CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

Michele Stanchina; Alessandro Pastore; Sean Devlin; Christopher Famulare; Eytan Stein; Justin Taylor

doi:10.1186/s13045-019-0771-0

Back

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

Journal article

Open access

Peer reviewed

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

Michele Stanchina, Alessandro Pastore, Sean Devlin, Christopher Famulare, Eytan Stein and Justin Taylor

Journal of hematology and oncology, Vol.12(1), pp.85-85

2019-08-22

DOI: https://doi.org/10.1186/s13045-019-0771-0

PMCID: PMC6704571

PMID: 31439003

Abstract

Life Sciences & Biomedicine

Science & Technology

Hematology

Oncology

We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.

Files and links (1)

url

https://doi.org/10.1186/s13045-019-0771-0View

Published (Version of record) Open

Metrics

5 Record Views

8 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.155 Leukemia Research
Web Of Science research areas: Hematology; Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
Creators: Michele Stanchina - University of Miami, Miller School of Medicine
Alessandro Pastore - Memorial Sloan Kettering Cancer Center
Sean Devlin - Memorial Sloan Kettering Cancer Center
Christopher Famulare - Memorial Sloan Kettering Cancer Center
Eytan Stein - Memorial Sloan Kettering Cancer Center
Justin Taylor - Memorial Sloan Kettering Cancer Center
Publication Details: Journal of hematology and oncology, Vol.12(1), pp.85-85
Publisher: Springer Nature
Number of pages: 4
Grant note: K08CA230319 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Conquer Cancer Foundation of the American Society of Clinical Oncology American Society of Hematology (ASH) Robert Wood Johnson Foundation; Robert Wood Johnson Foundation (RWJF) 1K08CA230319-01 / NIH/NCI; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) American Association for Cancer Research
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 31439003
PMCID: PMC6704571
Record Identifier: 991031713274902976